Newsletter Tool

Today’s Big News

Apr 9, 2024

#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED

Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics

AACR 24: AstraZeneca next-gen PARP inhibitor gives 'bang for your buck' over firstcomers

AACR 24: Oncologists look to the skies as partial solar eclipse passes over San Diego

Former bluebird execs hope to fly new startup to 'cutting edge' of gene therapy delivery tech

BrainStorm, plotting Lazerus-like recovery, aligns with FDA on design of phase 3b ALS trial

ACC: NewAmsterdam CEO hopes Amgen castoff can reduce heart disease by slashing small LDL

Featured

#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED

By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron

What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket.

Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics

By James Waldron

Just months after Bristol Myers Squibb boarded Karuna for its much-hyped schizophrenia drug, the biotech’s leadership has set sail in a new venture.

AACR 24: AstraZeneca next-gen PARP inhibitor gives 'bang for your buck' over firstcomers

By Annalee Armstrong

First-in-human results for AstraZeneca's saruparib showed an objective response rate of 48.8% in the 31 evaluable patients at the target dose. Median progression-free survival was 9.1 months.

AACR 24: Oncologists look to the skies as partial solar eclipse passes over San Diego

By Annalee Armstrong

When a rare solar eclipse passes overhead, what’s a scientist to do, but stop and take a look?

Former bluebird execs hope to fly new startup to 'cutting edge' of gene therapy delivery tech

By Helen Floersh

The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a new startup founded by two genetic medicine luminaries and run by former executives from bluebird bio is officially emerging from stealth mode to reveal its solutions to the industry.

BrainStorm, plotting Lazerus-like recovery, aligns with FDA on design of phase 3b ALS trial

By Nick Paul Taylor

BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis. A piece of the latest comeback strategy slotted into place Tuesday when the biotech revealed a written agreement with the FDA on the design of a phase 3b trial.

ACC: NewAmsterdam CEO hopes Amgen castoff can reduce heart disease by slashing small LDL

By Gabrielle Masson

NewAmsterdam Pharma has shared more obicetrapib data from a phase 2 trial at the 2024 American College of Cardiology (ACC) annual meeting in Atlanta. The new data include an analysis of small dense LDL-C, a strong predictor of residual risk of future cardiovascular events.

YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout

By James Waldron

China’s YS Biopharma has a good feeling about a phase 3 trial of its investigational PIKA rabies vaccine if a glimpse at the interim data is anything to go by.

ACC: Study shows J&J's Abiomed pump reduces deaths after widowmaker heart attacks

By Conor Hale

It's Impella's first positive result from a randomized trial showing increases in six-month survival after acute myocardial infarction and cardiogenic shock.

For biopharma M&A, the best returns come from small deals: analysts

By Kevin Dunleavy

Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions. Analysts from McKinsey and Project Farma explain why and offer advice on how to optimize deals.

'Sobering' study finds nearly no benefits from medical debt relief efforts

By Dave Muoio

An experimental review of medical debts relieved by the charity RIP Medical Debt in 2018 to 2020 showed near-negligible changes in credit, no improvement in financial well-being, no changes in repayment or utilization behaviors and worsened mental health among those with the most debts.

Fierce podcasts

Don’t miss an episode

The unrecognized threat of PAD

This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.

'The Top Line': The top money raisers in biotech

'Podnosis': A closer look at social prescribing and the impact of the arts on our health

Resources

eBook

Discover the future of mAb manufacturing

Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

Sponsored by: PPD®️ Laboratory Services